Featured Research

from universities, journals, and other organizations

Skin Cancer Breakthrough? New Molecule Shows Promise In Patients With Advanced Basal Cell Carcinoma

Date:
April 15, 2008
Source:
American Association for Cancer Research
Summary:
A novel molecule, GDC-0449, shrinks tumors for patients with advanced basal cell carcinoma with limited side effects, suggesting a viable new treatment option for patients with the advanced form of this cancer. "Basal cell carcinoma affects about one million people a year, and a very small fraction of these patients have disease that is not curable with surgery. We currently do not have any treatments that can effectively slow tumor growth in these advanced patients. This finding has enormous implications in this population," said one of the physicians involved with the research.

A novel molecule, GDC-0449, shrinks tumors for patients with advanced basal cell carcinoma with limited side effects, suggesting a viable new treatment option for patients with the advanced form of this cancer, according to research presented at the 2008 Annual Meeting of the American Association for Cancer Research.

"Basal cell carcinoma affects about one million people a year, and a very small fraction of these patients have disease that is not curable with surgery. We currently do not have any treatments that can effectively slow tumor growth in these advanced patients. This finding has enormous implications in this population," said Daniel D. Von Hoff, M.D., physician in chief at the Translational Genomics Research Institute (TGen) and chief medical officer for the Scottsdale Clinical Research Institute at Scottsdale Healthcare in Arizona.

GDC-0449 works by inhibiting the Hedgehog pathway. The Hedgehog ligands are a family of proteins that are important in tissue growth and repair. The ligands signal via two cell surface receptors called PTCH and SMO. Abnormal activation of Hedgehog signaling pathway because of mutations in PTCH and SMO is the cause of most basal cell carcinomas.

Von Hoff presented data from a phase I trial conducted at Scottsdale Healthcare, Karmanos Cancer Institute at Wayne State University, and the Sidney Kimmel Cancer Center at Johns Hopkins. This trial tested GDC-0449 in humans for the first time. Researchers enrolled nine patients with advanced basal cell carcinoma. Patients received oral doses of GDC-0449 once a day continuously.

Durable clinical benefit, defined as tumor stabilization or shrinkage visible on X-ray or other physical exam, was observed in eight of patients evaluated, and lasted a median of over 176 days. The first patient treated in the trial has shown clinical improvement for over 438 days, Von Hoff says, with mild side effects. "He came to us short of breath and in pain, but he has had a very dramatic response with this drug," Von Hoff said.

Of the original nine patients, two have had shrinkage of their tumors as measured by computerized tomography (CT) scans, four have had shrinkage or improvement of their tumors by clinical exam, two have had prolonged periods without tumor growth, and one has had significant tumor growth.

Further evaluations of the study participants measured the presence of GLI1, a genetic marker of Hedgehog pathway activity, in skin cells sampled from the participants. Among all patients tested to date, there was a reduction in this marker, indicating that the drug was affecting the Hedgehog pathway.

"The drug has been extremely well tolerated. Some patients lose a sense of taste, and there has been a small amount of hair loss and weight loss, but the toxicity has been mild," Von Hoff said.

Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients: Abstract LB-138


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Skin Cancer Breakthrough? New Molecule Shows Promise In Patients With Advanced Basal Cell Carcinoma." ScienceDaily. ScienceDaily, 15 April 2008. <www.sciencedaily.com/releases/2008/04/080414161050.htm>.
American Association for Cancer Research. (2008, April 15). Skin Cancer Breakthrough? New Molecule Shows Promise In Patients With Advanced Basal Cell Carcinoma. ScienceDaily. Retrieved August 30, 2014 from www.sciencedaily.com/releases/2008/04/080414161050.htm
American Association for Cancer Research. "Skin Cancer Breakthrough? New Molecule Shows Promise In Patients With Advanced Basal Cell Carcinoma." ScienceDaily. www.sciencedaily.com/releases/2008/04/080414161050.htm (accessed August 30, 2014).

Share This




More Health & Medicine News

Saturday, August 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
3 Things To Know About The Ebola Outbreak's Progression

3 Things To Know About The Ebola Outbreak's Progression

Newsy (Aug. 29, 2014) Here are three things you need to know about the deadly Ebola outbreak's progression this week. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins